Outlook Therapeutics raises ~$20.5M via warrant inductions; ONS-5010 meets noninferiority at week 12 in AMD trial

Outlook Therapeutics, Inc.

Exercised existing warrants for ~$17.8M gross (including $8.7M from GMS Ventures) and ~$2.7M from Syntone.
Issued inducement warrants for 14.1M shares (Tranche A immediate, Tranche B subject to shareholder approval) at $2.26 exercise price.
In NORSE EIGHT, ONS-5010 showed +5.5 letters BCVA improvement at week 12, meeting noninferiority (p=0.0043) vs ranibizumab.
Plans to resubmit BLA for ONS-5010 in Q1 2025 based on complete 12-week safety and efficacy data.
No retinal vasculitis reported; safety profile comparable to ranibizumab across all study timepoints.

item 1.01 item 3.02 item 3.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.